Enanta Pharmaceuticals Inc
ENTA
NASDAQ
Biotechnology
$13.16
USD
-0.28 (-2.08%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $391.45M
Volume 173.4K
Revenue
$65.26M
TTM
+0.7%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-63.23M
TTM
+31.3%
YoY
Operating Cash Flow
$-35.32M
TTM
-52.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|
Revenue | 18.3 | 15.1 | 18.6 | 17.2 | 14.4 |
YoY Growth | +1.9% | +3.5% | +9.8% | +15.0% | -21.6% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 18.3 | 15.1 | 18.6 | 17.2 | 14.4 |
Selling, General & Administrative | 10.0 | 9.7 | 9.0 | 9.6 | 9.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 37.2 | 33.5 | 29.9 | 29.0 | 31.6 |
Operating Income | -18.9 | -18.4 | -11.3 | -11.9 | -17.2 |
EBITDA | -17.7 | -17.1 | -10.0 | -10.6 | -16.1 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.7 | -0.3 | -0.7 | -1.2 | -2.2 |
Income Before Income Taxes | -18.2 | -18.7 | -11.9 | -13.1 | -19.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -18.3 | -18.7 | -11.9 | -13.1 | -19.5 |
Consolidated Net Income / Loss | -18.3 | -18.7 | -11.9 | -13.1 | -19.5 |
Net Income Attributable to Common Shareholders | -18.3 | -18.7 | -11.9 | -13.1 | -19.5 |
Basic EPS | -$0.85 | -$0.87 | -$0.42 | -$0.45 | -$0.67 |
Diluted EPS | -$0.85 | -$0.87 | -$0.42 | -$0.45 | -$0.67 |
Basic Shares Outstanding | 21.4M | 21.4M | 28.7M | 29.0M | 29.1M |
Diluted Shares Outstanding | 21.4M | 21.4M | 28.7M | 29.0M | 29.1M |